Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471985 | 0.85 | CYP19A1 (0.54) | CYP19A1TBXAS1MAPK1KDM4EL3MBTL1 | |
| SCHEMBL13108504 | 0.83 | CYP19A1 (0.58) | QPCTCYP19A1TBXAS1ALOX15HMOX1 | |
| SCHEMBL9240603 | 0.81 | QPCT (0.60) | QPCTCYP19A1MAPK1ALOX15NOS1 | |
| SCHEMBL9236717 | 0.78 | QPCT (0.57) | QPCTCYP19A1MAPK1ALOX15NOS2 | |
| SCHEMBL9237032 | 0.76 | HTT (0.61) | QPCTKMT2ANOS1KDM4E | |
| SCHEMBL21637747 | 0.76 | SMN1; SMN2 (0.64) | QPCTCYP19A1KMT2AMAPK1ALOX15 | |
| SCHEMBL108087 | 0.74 | TAAR1 (0.77) | TAAR1 | |
| SCHEMBL20689718 | 0.73 | ADRA1D (0.65) | TAAR1 | |
| SCHEMBL28150001 | 0.73 | CYP19A1 (0.50) | CYP19A1 | |
| SCHEMBL7067249 | 0.72 | NOS2 (0.57) | MAPK1ALOX15NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NORTHWEST A & F UNIVERSITY (CN) | 2023-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680062-B2 | 3,4-methylenedioxyphenylimidazolylethanonexime ether derivative, preparation method and use thereof, and drug for the treatment of Alzheimer's disease | NOS3, CYP51A1, NOS1 | QPCT 599/4885TAAR1 3506/4885CYP19A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.